{"id":53544,"date":"2023-09-20T09:47:38","date_gmt":"2023-09-20T09:47:38","guid":{"rendered":"https:\/\/medsname.com\/tykerb\/"},"modified":"2026-04-30T16:30:28","modified_gmt":"2026-04-30T16:30:28","slug":"tykerb","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/tykerb\/","title":{"rendered":"Tykerb"},"content":{"rendered":"<div class=\"medsbase-tldr-answer\" style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<h3 style=\"margin-top:0;\">R\u0103spuns rapid<\/h3>\n<p style=\"margin-bottom:0;\"><strong>Tykerb<\/strong> \u2014 Lapatinib 250 mg (GlaxoSmithKline). Inhibitor dual EGFR + HER2 TKI pentru cancerul mamar HER2-pozitiv avansat sau metastatic (\u00een asociere cu capecitabin\u0103 dup\u0103 e\u0219ecul tratamentului cu trastuzumab, sau cu letrozol ca terapie de prim\u0103 linie \u00een boala HR+\/HER2+ la femeile postmenopauzale).<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f7f7f7;border-left:4px solid #2c7cb0;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0 0 6px 0;\"><strong>Ce beneficii ofer\u0103 MedsBase:<\/strong><\/p>\n<ul style=\"margin:6px 0 0 22px;padding:0;list-style:disc;\">\n<li>produc\u0103tor certificat WHO-GMP<\/li>\n<li>Ambalaj discret \u00een plic simplu<\/li>\n<li>Livrare \u00een toat\u0103 lumea<\/li>\n<li>Evaluat de peste 1.400 de clien\u021bi (<a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">cite\u0219te recenziile<\/a>)<\/li>\n<\/ul>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"background:#eef7ee;border-left:4px solid #4caf50;padding:10px 14px;margin:14px 0;border-radius:3px;\">\ud83d\udce6 <strong>Garan\u021bia de retransmitere:<\/strong> dac\u0103 comanda dvs. nu a ajuns \u00een 20 de zile lucr\u0103toare de la expediere, o retransmitem f\u0103r\u0103 costuri suplimentare. <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\">Cite\u0219te politica<\/a>.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Tykerb este expediat de la un produc\u0103tor certificat WHO-GMP \u00een ambalaj neutru, facturat printr-un procesor de pl\u0103\u021bi reglementat (descrierea pe extrasul de cont va indica un procesor de pl\u0103\u021bi reglementat \u2014 niciodat\u0103 MedsBase sau numele medicamentului). Fiecare comand\u0103 beneficiaz\u0103 de Garan\u021bia noastr\u0103 de Reexpediere pe 20 de zile lucr\u0103toare.<\/p>\n<div class=\"medsbase-specialist-strip\" style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0;\"><strong>\u26a0\ufe0f Terapie oncologic\u0103 supravegheat\u0103 de specialist<\/strong> \u2014 acest medicament este ini\u021biat, monitorizat \u0219i \u00eentrerupt de un oncolog sau hematolog. Dozarea depinde de tipul tumorii, stadiul, suprafa\u021ba corporal\u0103, func\u021bia organelor \u0219i terapia concomitant\u0103. Autotratamentul nu este adecvat; informa\u021biile de mai jos au scop educa\u021bional \u0219i sus\u021bin conversa\u021biile informate cu specialistul dumneavoastr\u0103.<\/p>\n<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>Principiile clasei TKI<\/strong><br \/>Inhibitorii de tirozin-kinaz\u0103 sunt terapii orale \u021bintite. Ele necesit\u0103 ini\u021biere de c\u0103tre specialist, monitorizare terapeutic\u0103 continu\u0103 (acolo unde este disponibil\u0103) \u0219i gestionarea toxicit\u0103\u021bilor specifice clasei. Conformitatea este critic\u0103 \u2014 dozele ratate risc\u0103 e\u0219ecul tratamentului. Majoritatea TKI sunt substraturi CYP3A4 cu interac\u021biuni medicamentoase importante.<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>Hepatotoxicitate + disfunc\u021bie cardiac\u0103<\/strong><br \/>Hepatotoxicitate sever\u0103 raportat\u0103. Teste hepatice de baz\u0103 \u0219i lunare \u00een primele 6 luni. \u00centrerupe\u021bi dac\u0103 testele hepatice dep\u0103\u0219esc de 3 ori limita superioar\u0103 normal\u0103 (ULN) cu simptome. Poate ap\u0103rea reducere a frac\u021biei de ejec\u021bie ventricular\u0103 st\u00e2ng\u0103 (LVEF) \u2014 ecocardiogram\u0103 de baz\u0103 \u0219i periodic\u0103. Prelungire a intervalului QT. Administrare pe stomac gol (1 or\u0103 \u00eenainte\/dup\u0103 mese) \u2014 alimentele cresc semnificativ biodisponibilitatea \u0219i toxicitatea.<\/div>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3>Ce este un TKI?<\/h3>\n<p>Inhibitorii de tirozin-kinaz\u0103 blocheaz\u0103 c\u0103i specifice de semnalizare care stimuleaz\u0103 cre\u0219terea celulelor canceroase. Fiecare TKI este selectiv pentru \u021binte diferite (EGFR pentru gefitinib\/erlotinib; multikinaz\u0103 pentru sorafenib\/sunitinib; BCR-ABL pentru nilotinib\/imatinib; BTK pentru ibrutinib; JAK pentru ruxolitinib; CDK4\/6 pentru palbociclib).<\/p>\n<h3>Efecte secundare?<\/h3>\n<p>Semn\u0103tur\u0103 de clas\u0103: erup\u021bie cutanat\u0103 (adesea coreleaz\u0103 cu r\u0103spunsul la inhibitorii EGFR), diaree, oboseal\u0103, reac\u021bie cutanat\u0103 m\u00e2n\u0103-picior, hipertensiune (multikinaz\u0103), hepatotoxicitate, prelungire QT. Fiecare TKI are un profil specific.<\/p>\n<h3>Interac\u021biuni medicamentoase?<\/h3>\n<p>Majoritatea TKI sunt substraturi CYP3A4. Inhibitorii puternici (azole, macrolide, ritonavir, grapefruit) cresc nivelurile \u0219i toxicitatea; inductorii puternici (rifampicin\u0103, fenitoin\u0103, carbamazepin\u0103, sun\u0103toarea) scad nivelurile \u0219i risc\u0103 e\u0219ecul tratamentului.<\/p>\n<h3>Se ia cu m\u00e2ncare?<\/h3>\n<p>Unele TKI (lapatinib, erlotinib) pe stomacul gol (m\u00e2ncarea cre\u0219te biodisponibilitatea variabil). Altele (gefitinib, sorafenib) cu sau f\u0103r\u0103 m\u00e2ncare. Instruc\u021biunile specifice depind de molecul\u0103 \u2014 confirma\u021bi cu oncologul prescriitor.<\/p>\n<h3>Cum se monitorizeaz\u0103 r\u0103spunsul?<\/h3>\n<p>Imagistic\u0103 (CT\/RMN\/PET) la fiecare 2-3 luni la \u00eenceput; markeri tumorali dac\u0103 sunt aplicabili. Tratamentul continu\u0103 c\u00e2t exist\u0103 beneficiu; se schimb\u0103 la progresie sau toxicitate inacceptabil\u0103.<\/p>\n<h3>Rezisten\u021b\u0103?<\/h3>\n<p>Rezisten\u021ba la TKI se dezvolt\u0103 \u00een timp (de obicei 9-18 luni \u00een tumori solide). Mecanisme: muta\u021bii \u021bint\u0103 (T790M pentru EGFR, T315I pentru BCR-ABL), activarea c\u0103ilor alternative, supraexprimarea \u021bintei. TKI de nou\u0103 genera\u021bie (osimertinib, ponatinib) dep\u0103\u0219esc muta\u021biile specifice de rezisten\u021b\u0103.<\/p>\n<h3>Ce fac dac\u0103 uit o doz\u0103?<\/h3>\n<p>Lua\u021bi c\u00e2nd v\u0103 aminti\u021bi dac\u0103 este aceea\u0219i zi \u0219i dac\u0103 mai sunt &gt;6 ore p\u00e2n\u0103 la urm\u0103toarea doz\u0103. Altfel omite\u021bi \u2014 nu dubla\u021bi doza. Instruc\u021biunile specifice variaz\u0103 \u00een func\u021bie de medicament; confirma\u021bi cu echipa de oncologie.<\/p>\n<h3>Sarcin\u0103?<\/h3>\n<p>Toate TKI-urile sunt teratogene \u2014 contracep\u021bie eficient\u0103 \u00een timpul \u0219i pentru cel pu\u021bin 4-6 luni dup\u0103 tratament pentru ambii parteneri.<\/p>\n<h3>Monitorizare cardiac\u0103?<\/h3>\n<p>TKI-uri multichinazice (sorafenib, sunitinib): monitorizare TA, ECG (QT), ecocardiogram\u0103 \u00een cazuri selectate. TKI-uri BCR-ABL (nilotinib): ECG obligatoriu la ini\u021biere \u0219i \u00een follow-up \u2014 prelungire QT.<\/p>\n<h3>Rentabilitate?<\/h3>\n<p>TKI-urile generice sunt produse pe scar\u0103 larg\u0103 sub licen\u021be voluntare \u00een India \u0219i alte jurisdic\u021bii. Pre\u021burile genericulor indiene sunt semnificativ mai mici dec\u00e2t ale echivalentelor de marc\u0103. Calitatea \u0219i bioechivalen\u021ba sunt bine documentate.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Alte Medicamente Anticanceroase<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/xeloda\/\">Xeloda<\/a> \u2014 capecitabin\u0103 500 mg \u2014 prodrog oral de 5-FU pentru cancerul de s\u00e2n\/colorectal\/gastric<\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/altraz\/\">Altraz<\/a> \u2014 anastrozol 1 mg \u2014 inhibitor de aromataz\u0103 pentru cancerul de s\u00e2n la femei postmenopauzale<\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/xbira\/\">Xbira<\/a> \u2014 abirateron\u0103 250 mg \u2014 inhibitor CYP17 pentru cancerul metastatic de prostat\u0103<\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/zoldria\/\">Zoldria<\/a> \u2014 acid zoledronic IV \u2014 pentru metastaze osoase \u0219i hipercalcemie<\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/actorise\/\">Actorise<\/a> \u2014 darbepoetin alfa \u2014 pentru anemie indus\u0103 de chimioterapie<\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:18px 0;border-radius:3px;font-size:.95em;\"><strong>Disclaimer medical:<\/strong> Tratamentul cancerului este foarte individualizat. Medicamentul specific, doza, programul, monitorizarea \u0219i \u00eengrijirea de sus\u021binere trebuie stabilite de un oncolog sau hematolog calificat, pe baza biologiei tumorii, stadializ\u0103rii, comorbidit\u0103\u021bilor \u0219i obiectivelor terapiei. Aceast\u0103 informa\u021bie are caracter educa\u021bional; nu \u00eenlocuie\u0219te sfatul medical profesionist.<\/div>","protected":false},"excerpt":{"rendered":"<p>Tykerb (Lapatinib 250 mg) \u2014 GSK inhibitor dual EGFR + HER2 TKI pentru cancerul mamar HER2-pozitiv avansat sau metastatic, \u00een asociere cu capecitabin\u0103 sau letrozol.<\/p>","protected":false},"featured_media":53545,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223],"product_tag":[],"class_list":{"0":"post-53544","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","10":"first","11":"outofstock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/53544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=53544"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/53545"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=53544"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=53544"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=53544"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=53544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}